Literature DB >> 8646692

Recursive partitioning analysis of 2105 patients treated in Radiation Therapy Oncology Group studies of head and neck cancer.

J S Cooper1, N C Farnan, S O Asbell, M Rotman, V Marcial, K K Fu, W G McKenna, B Emami.   

Abstract

BACKGROUND: The Radiation Therapy Oncology Group conducts large-scale prospective, randomized trials to test new concepts in cancer patient care and provide information about pretreatment and treatment factors that may influence outcome.
METHODS: Recursive partitioning analysis (RPA) was used to examine the data derived from 2105 patients. RPA grouped patients according to the influence of tumor, of host, and of treatment variables on outcome.
RESULTS: For survival, the most important factor was T classification. For lesions less than T3, the primary tumor was the next most important factor, whereas for T3 and T4 lesions the Karnofsky score was the next most predictive factor. Six distinct groups were formed by RPA, with median survivals ranging from 6.8 to 151.8 months. For local-regional control, the N classification was the most important factor. For patients with no adenopathy, T classification was the next most important factor, whereas for patients with adenopathy, the number of treatment fractions was the next most important factor. Such analysis created 5 distinct groups. In the most favorable, the median time to local-regional relapse has not yet been reached. In the least favorable group, fewer than 50% of the patients experienced complete response at any time following treatment.
CONCLUSIONS: RPA clarifies the relative importance and potential interactions of pretreatment and treatment variables and should permit more accurate stratification of patients in future trials.

Entities:  

Mesh:

Year:  1996        PMID: 8646692     DOI: 10.1002/(SICI)1097-0142(19960501)77:9<1905::AID-CNCR22>3.0.CO;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Prospective imaging assessment of mortality risk after head-and-neck radiotherapy.

Authors:  Benjamin J Moeller; Vishal Rana; Blake A Cannon; Michelle D Williams; Erich M Sturgis; Lawrence E Ginsberg; Homer A Macapinlac; J Jack Lee; K Kian Ang; K S Clifford Chao; Gregory M Chronowski; Steven J Frank; William H Morrison; David I Rosenthal; Randal S Weber; Adam S Garden; Scott M Lippman; David L Schwartz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-02-18       Impact factor: 7.038

2.  DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy.

Authors:  Benjamin J Moeller; John S Yordy; Michelle D Williams; Uma Giri; Uma Raju; David P Molkentine; Lauren A Byers; John V Heymach; Michael D Story; J Jack Lee; Erich M Sturgis; Randal S Weber; Adam S Garden; K Kian Ang; David L Schwartz
Journal:  Clin Cancer Res       Date:  2011-02-24       Impact factor: 12.531

3.  High-dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma.

Authors:  Gilberto de Castro; Igor Moisés Longo Snitcovsky; Eloísa Maria Mello Santiago Gebrim; Glauber Moreira Leitão; Wladimir Nadalin; Alberto Rossetti Ferraz; Miriam Hatsue Honda Federico
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-07-21       Impact factor: 2.503

4.  Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck.

Authors:  Silke Tribius; Stefanie Kronemann; Yasemin Kilic; Ursula Schroeder; Samer Hakim; Steven E Schild; Dirk Rades
Journal:  Strahlenther Onkol       Date:  2009-10-06       Impact factor: 3.621

5.  Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head and Neck Squamous Cell Carcinoma.

Authors:  Aaron J Grossberg; Sasikarn Chamchod; Clifton D Fuller; Abdallah S R Mohamed; Jolien Heukelom; Hillary Eichelberger; Michael E Kantor; Katherine A Hutcheson; G Brandon Gunn; Adam S Garden; Steven Frank; Jack Phan; Beth Beadle; Heath D Skinner; William H Morrison; David I Rosenthal
Journal:  JAMA Oncol       Date:  2016-06-01       Impact factor: 31.777

6.  Matched pair analysis to evaluate the impact of hospitalization during radiation therapy as an early marker of survival in head and neck cancer patients.

Authors:  Hye Ri Han; Gregory M Hermann; Sung Jun Ma; Austin J Iovoli; Kimberly E Wooten; Hassan Arshad; Vishal Gupta; Ryan P McSpadden; Moni A Kuriakose; Michael R Markiewicz; Jon M Chan; Mary E Platek; Andrew D Ray; Fangyi Gu; Wesley L Hicks; Elizabeth A Repasky; Anurag K Singh
Journal:  Oral Oncol       Date:  2020-06-16       Impact factor: 5.337

7.  Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multi-morbid patient: a single-centre experience.

Authors:  Alexandra D Jensen; Zazie P Bergmann; Helena Garcia-Huttenlocher; Kolja Freier; Jürgen Debus; Marc W Münter
Journal:  Head Neck Oncol       Date:  2010-11-26

8.  Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Authors:  Alexandra D Jensen; Jürgen Krauss; Wilko Weichert; Zazie P Bergmann; Kolja Freier; Jürgen Debus; Marc W Münter
Journal:  Radiat Oncol       Date:  2011-09-23       Impact factor: 3.481

9.  Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy.

Authors:  Aaron J Grossberg; Abdallah S R Mohamed; Hesham Elhalawani; William C Bennett; Kirk E Smith; Tracy S Nolan; Bowman Williams; Sasikarn Chamchod; Jolien Heukelom; Michael E Kantor; Theodora Browne; Katherine A Hutcheson; G Brandon Gunn; Adam S Garden; William H Morrison; Steven J Frank; David I Rosenthal; John B Freymann; Clifton D Fuller
Journal:  Sci Data       Date:  2018-09-04       Impact factor: 6.444

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.